Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study
- PMID: 20456259
- DOI: 10.1111/j.1755-3768.2010.01904.x
Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study
Abstract
Purpose: To investigate how prophylactic anterior chamber paracentesis affects the intraocular pressure (IOP) after intravitreal pegaptanib injections.
Methods: In this prospective study, 41 eyes of 41 patients receiving intravitreal pegaptanib injections were randomly assigned either to receive anterior chamber paracentesis prior to the injection (Group A, 20 patients, n = 35 injections) or not (Group B, 21 patients, n = 38 injections). IOP was measured before the pegaptanib injection (T0) and 2 min (T1), 30 min (T2) and 1 week (T3) after the injection. A four-point scale was used to evaluate the subjective pain experienced during the procedure.
Results: The mean IOP at T1 was 15.3 ± 7.5 mmHg in group A and 47.1 ± 24.1 mmHg in group B (difference -31.85 mmHg, 95% Confidence interval -40.13 to -23.56; p < 0.0001). In 45% of the injections without paracentesis, IOP was higher than 50 mmHg 2 min after the pegaptanib injection. No significant difference in IOP was observed at T0, T2 and T3 between the two study groups. The mean pain scores did not differ significantly (0.97 in group A versus 1.32 in group B; p = 0.08).
Conclusions: The results suggest that prophylactic anterior chamber paracentesis helps to prevent the high postoperative IOP spike without causing patients any additional pain.
© 2010 The Authors. Journal compilation © 2010 Acta Ophthalmol.
Similar articles
-
Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study.Graefes Arch Clin Exp Ophthalmol. 2017 Sep;255(9):1705-1712. doi: 10.1007/s00417-017-3702-1. Epub 2017 Jun 14. Graefes Arch Clin Exp Ophthalmol. 2017. PMID: 28616715 Clinical Trial.
-
Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.Arch Ophthalmol. 2010 Dec;128(12):1523-7. doi: 10.1001/archophthalmol.2010.297. Arch Ophthalmol. 2010. PMID: 21149773
-
EFFECT OF SERIAL ANTERIOR CHAMBER PARACENTESIS ON SUSTAINED INTRAOCULAR PRESSURE ELEVATION IN PATIENTS RECEIVING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.Retina. 2019 Oct;39(10):1959-1964. doi: 10.1097/IAE.0000000000002314. Retina. 2019. PMID: 30234855
-
Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab.Eye (Lond). 2009 Jan;23(1):181-5. doi: 10.1038/sj.eye.6702938. Epub 2007 Aug 10. Eye (Lond). 2009. PMID: 17693999
-
The Effect of Anti-Vascular Endothelial Growth Factor Agents on Intraocular Pressure and Glaucoma: A Report by the American Academy of Ophthalmology.Ophthalmology. 2019 Apr;126(4):611-622. doi: 10.1016/j.ophtha.2018.11.019. Epub 2018 Nov 22. Ophthalmology. 2019. PMID: 30472176 Review.
Cited by
-
Can intravitreal injections with higher volume cause higher intraocular eye pressure? Considerations for anti-complement injections in normal and glaucomatous eyes.Int J Retina Vitreous. 2023 Dec 14;9(1):80. doi: 10.1186/s40942-023-00517-1. Int J Retina Vitreous. 2023. PMID: 38098108 Free PMC article.
-
The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy.Pharmaceutics. 2025 Mar 20;17(3):394. doi: 10.3390/pharmaceutics17030394. Pharmaceutics. 2025. PMID: 40143057 Free PMC article. Review.
-
Sustained Elevation of Intraocular Pressure Associated with Intravitreal Administration of Anti-vascular Endothelial Growth Factor: A Systematic Review and Meta-Analysis.Sci Rep. 2016 Dec 21;6:39301. doi: 10.1038/srep39301. Sci Rep. 2016. PMID: 28000707 Free PMC article.
-
Anterior chamber paracentesis during intravitreal injections in observational trials: effectiveness and safety and effects.Int J Retina Vitreous. 2019 Mar 6;5:8. doi: 10.1186/s40942-019-0157-z. eCollection 2019. Int J Retina Vitreous. 2019. PMID: 30873293 Free PMC article.
-
Acute and subacute intraocular pressure and macular microvascular structure changes after intravitreal ranibizumab injection in eyes with branch retinal vein occlusion.BMC Ophthalmol. 2023 Apr 18;23(1):160. doi: 10.1186/s12886-023-02889-2. BMC Ophthalmol. 2023. PMID: 37072736 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources